GH2

Across TCGA pan-cancer cohorts, GH2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated GH2 data layer compared with 19 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher GH2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GH2 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

LUAD, LIHC, and STAD are the cancer types where GH2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.248	0.754	<.001	26	view →
LIHC	OS	Median	All	0.144	0.688	.013	9	view →
STAD	OS	Median	II,III,IV	1.000	0.667	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

GH2–LUAD (OS)

Open the LUAD breakdown →